CMVLF Stock News Cellectis Romainvil (CMVLF) 18.7600 07/13/2014

New Post Public Reply Private Reply Replies (0) Message Board

Jul 13, 2014 at 10:51 PM

Cellectis Romainvil (CMVLF) 18.7600 $CMVLF

Cellectis R&D / Analyst Day
Business Wire - Wed Jun 25, 11:18AM CDT
Regulatory News:

Biotech Funding Deals and Partnerships 2014: Analysis of 56 Recent Venture Capital and Corporate Capital Funding and Other Transactions
M2 - Wed Jun 25, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6b8dm/biotech_funding) has announced the addition of the "Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions" report to their offering. Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic. Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector. Included in the report's coverage are the following data points - 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential - Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions) - Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions) - Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million - Number of Biotech Series A Companies by Indication Oncology, - Platform Discovery, Diagnostics, CNS, Autoimmune) - Biotech Total Deal Value, 2005-2012 - IPO Statistics - Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013 Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs. This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma. The following are among the companies covered in this report: - Abbott - AC Immune SA - Adimab - Aileron Therapeutics Inc. - Atara Biotherapeutics - Cellectis - Clarus Ventures - CoStim Pharmaceuticals - Covagen AG - Dicerna Pharmaceuticals Inc. - Editas Medicine - Enanta Pharmaceuticals Inc. - Endocyte Inc. - Mannkind Corp. - Melinta Therapeutics - Micromet - Novartis - OncoMed - Onyx Pharmaceuticals Inc. - Otonomy Inc. - Pharmasset - Seattle Genetics Inc. - Royalty Pharma - Roche - Sutro Biopharma Inc. - Thesan Pharmaceuticals Inc. - UCB Inc. - Voyager Therapeutics - Xenon Pharmaceuticals Inc. - Xoma Corp. For more information visit http://www.researchandmarkets.com/research/r6...ch_funding

Cellectis' UCART19 Receives Advanced-Therapy Medicinal Product Classification from EMA
Business Wire - Mon Jun 23, 11:14AM CDT
Regulatory News :

Cellectis To Participate in the Piper Jaffray GenomeRx Symposium on June 23, 2014
Business Wire - Thu Jun 19, 11:00AM CDT
Dr. David Sourdive, PhD, EVP Corporate Development at Cellectis (Paris:ALCLS) (Alternext: ALCLS.PA) will be attending Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014 in The Yale Club, New York.

Pfizer And Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration
Business Wire - Wed Jun 18, 12:00AM CDT
Pfizer Inc. (NYSE

FE) and Cellectis (Paris:ALCLS) today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. Cellectis' CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient's own T-cells to target tumor cells).

Cellectis to Present New Data Update on Its Allogeneic CAR T Cell Therapeutics at the 19th Congress of the European Hematology Association (EHA)
Business Wire - Tue Jun 10, 11:00AM CDT
Dr. Julianne Smith, PhD, VP CART Development at Cellectis (Paris:ALCLS) and Dr. Roman Galetto, PhD, Project Leader, will be attending the 19th Congress of the European Hematology Association in Milan, Italy from June 12th to 15th, 2014.

Cellectis enters into an agreement with CELLforCURE for the cGMP manufacturing of allogeneic CART cells
Business Wire - Mon Jun 09, 11:08AM CDT
Regulatory News:

Cellectis and Accelera (Nerviano Medical Sciences Group) Sign an Agreement to Complete Preclinical Studies of Cellectis' Lead Product Candidate UCART19
Business Wire - Thu Jun 05, 11:00AM CDT
Regulatory News:

Cellectis and Thermo Fisher Scientific Enter Into Agreements on TALEN(TM), a Leading Gene Editing Technology
Business Wire - Thu Jun 05, 1:00AM CDT
Regulatory News:

Cellectis plant sciences reports improvement of oil content in algae
Business Wire - Thu May 29, 11:00AM CDT
Regulatory News:

Cellectis will be Present at the ASCO Annual Meeting
PR Newswire - Tue May 27, 11:00AM CDT
André Choulika, PhD, CEO of Cellectis (Alternext: ALCLS) and Mathieu Simon, MD, Executive Vice President will be attending this year's ASCO meeting in Chicago, IL on May the 30th to June 3rd, 2014.

Cellectis Plant Sciences Reports Generation of High Oleic Soybean in Journal of Plant Biotechnology
Business Wire - Fri May 23, 11:40AM CDT
Regulatory News:

TAL-effector Nuclease: The USPTO Issues a Fourth Patent Licensed to Cellectis
Business Wire - Mon May 19, 11:30AM CDT
Regulatory News:

Cellectis Announces the Closing of EUR20.5 M Share Capital Increase Subscribed on March 24, 2014 by U.S. Biotechnology Specialist Institutional Investors
Business Wire - Mon Mar 31, 1:31PM CDT
Regulatory News:

Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors
Business Wire - Mon Feb 17, 1:03PM CST
Regulatory News:

US Patent Institutions Recognize the Patentability of Institut Pasteur/Cellectis Early Inventions on Meganucleases
Business Wire - Wed Feb 05, 11:00AM CST
Regulatory News:

Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models
Business Wire - Tue Feb 04, 11:44AM CST
Regulatory News:

Cellectis Plant Sciences and Bayer CropScience Extend Their Partnership to Improve Crops by Gene Editing
Business Wire - Thu Jan 30, 12:00AM CST
Regulatory News:

Axxam and Cellectis Bioresearch Announce Their Collaboration to Offer a New Generation of Cell Based Assays
Business Wire - Fri Jan 17, 11:00AM CST
Regulatory News:

Cellectis Plant Sciences Announce the Finalization of the First Glycosylation Lines of Their Program
Business Wire - Thu Jan 09, 10:59AM CST
Regulatory News :

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CSL Names Deborah Waterhouse as CEO in Strategic Move

A Key Transition: Deborah Waterhouse Takes the Helm In a move that's sure to jolt the biopharma sphere, CSL Limited just handed the CEO reins over to Deborah Waterhouse. Set to start officially on February 1, 2027, this strategic appointment seems well plotted after a diligent global hunt by CSL's board for someone who can drive their enterprise into its next surge of...

Bolt Teams with NVIDIA for Europe AV Expansion

Racing Towards an Autonomous Future Well, hold onto your seats because the European roads will soon witness one hell of a technological trip—with an autonomous twist. Bolt, in cahoots with NVIDIA and Lucid, is plotting to roll out a massive fleet of autonomous vehicles just gearing up to hit the streets. The project's kicking off in Madrid in 2027 and aims to sprinkle...

Ashford Hospitality Trust: Fee Waiver and Share Buyback

Strategic Moves in a Challenging Market When it rains, it pours. Ashford Hospitality Trust (NYSE: AHT), the real estate investment trust that's got its fingers in the hotel industry pie, is shaking things up with some bold maneuvers. The company just dropped a bombshell: it's waiving a $17 million advisory fee, buying back shares, and terminating its at-the-market (ATM)...

Hyliion Legal Woes Shake Investor Confidence

Legal Storm Brews Over Hyliion Investments If you think riding the stock market is like sailing a calm sea, wake up. Hyliion Holdings Corp. (NYSE:HYLN) finds itself steaming headlong into rough waters. A securities class action lawsuit, Olmeta v. Hyliion Holdings Corp., accuses the company of embellishing its ambitions. The lawsuit cites potential wrongdoing in a...

Partner Climbs 25 Spots on ENR's Environmental Firm List

A Leap Forward in Environmental Expertise Alright, folks, let's dive into some real grit. Partner Engineering and Science, Inc. has pulled off a neat little trick. They've jumped up 25 spots on the 2026 Engineering News-Record's Top 200 Environmental Firms list. They’ve been making this list for 14 years straight, and that's no fluke. It's a hard road, especially when...

Network Brainiacs Expands Footprint into Maryland Market

Network Brainiacs Steps into Maryland Territory If you're in the tech services game, expansion stories are the bread and butter of this business. Network Brainiacs, a seasoned veteran in the managed IT and cybersecurity sectors, has taken their first big step into Maryland by acquiring Computer Enhancement Systems (CES), a notable player in the field, as of September 1,...

Glint: Lovense's New Era in Intimacy Tech

From Thrill to Touch: The Glint Debut Screw the traditional remote control for sex toys! Lovense is straight up flipping the script with Glint. This isn't about adding more buttons or connecting another app. We're talking about a butt plug that lets your partner's thrust set the whole vibe. Forget fumbling with phones in the heat of the moment—this toy syncs your...

Millrose Investors Face Unveiling of Financial Missteps

A Cold Shower for Millrose Properties' Investors Investing in Millrose Properties, Inc. (NYSE: MRP) didn't quite pan out as some folks hoped. On the heels of Hunterbrook's report about dubious deals, the Company's stock tumbled 8.53%, smacking investors with a not-so-gentle reminder of market realities. Sure, stocks can dip and dive like a rollercoaster, but when it...

Oberndorf, Bascom Snap Up San Jose Flats for $53M

Well, isn’t this just a spicy tidbit from the real estate frontier? Oberndorf Real Estate Management and The Bascom Group are strutting into San Jose with a hefty $53.1 million deal that snags them the Museum Park Apartments. These guys aren't just dipping their toes; they’re cannonballing into the market with style. Now, exactly what does it mean for you and me?...

Papa John's Legal Woes: Class Action Lawsuit Hits Hard

A Hot Slice of Legal Trouble for Papa John's Ah, what a steaming mess Papa John's seems to have landed in! And not the good kind with extra cheese. The lawsuit bell tolls for them, reminding investors that even the big guys can get burned. This time, it's for allegedly not having their story straight when it came to market expectations and promotional tactics. Under the...